Kaléo receives $150 million debt financing

  •  | 
Print this page

Richmond-based kaléo announced Monday it has entered into a $150 million debt facility with Nevada-based PDL BioPharma. The funds will allow kaléo to support the commercialization of its anti-overdose-injector EVZIO, invest in the development of key pipeline products and repay existing debt.

EVZIO, approved by the Federal Drug Administration last week, is a pre-filled, single-use auto-injector that can be used by family members or caregivers to treat a person known or suspected to have an opioid overdose.

PDL BioPharma manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies

Reader Comments

comments powered by Disqus

showhide shortcuts